gdc

ASCO 2020 Highlights

Maintenance Treatment with Bavencio a New Standard of Care for Patients with Advanced Bladder Cancer
Bladder Cancer
Interim analysis of the phase 3 JAVELIN Bladder 100 trial showed that maintenance therapy with the PD-L1 inhibitor Bavencio (avelumab) plus best supportive care significantly prolonged survival compared with the current best supportive care alone in patients with advanced urothelial carcinoma, the most common type of bladder cancer, that did not progress (get worse) after treatment with first-line platinum-based chemotherapy.
Libtayo Reduces Pain, Improves Quality of Life  in Patients with Advanced Cutaneous  Squamous-Cell Carcinoma
ImmunotherapySkin Cancer
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
Libtayo Extends Survival in Patients with Metastatic Cutaneous Squamous-Cell Carcinoma
Skin Cancer
New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
The Combination of Cabometyx plus Tecentriq Improves Outcomes in Patients with Advanced Prostate Cancer
Prostate Cancer
Results of a new study showed that the combination of Cabometyx (cabozantinib) and the immune checkpoint inhibitor Tecentriq (atezolizumab) was safe and effective in men with metastatic (spreading) castration-resistant prostate cancer, the most common type of prostate cancer.
Lynparza Improves Quality of Life in Men with Metastatic Prostate Cancer
Prostate Cancer
The PARP inhibitor Lynparza (olaparib), a type of drug that is usually used for the treatment of women with ovarian cancer, has also been studied in men with prostate cancer. The results of the PROfound clinical trial were recently presented at the 2020 ASCO annual meeting by Antoine Thiery-Vuillemin, MD, PhD, Centre Hospitalier de Besançon, France.
Lynparza Extends Survival by More Than 1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation, Should Become Standard Maintenance Therapy
Ovarian Cancer
The follow-up results of more than 5 years of the multicenter phase 3 SOLO2 clinical trial of women with ovarian cancer were presented at the 2020 ASCO annual meeting, showing improved survival with the use of Lynparza (olaparib) compared with placebo.
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
Multiple Myeloma
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
New TIL Immunotherapy Shows Promise in Patients with Inoperable or Metastatic Melanoma
Melanoma
Several immunotherapies known as immune checkpoint inhibitors are available today for patients with melanoma, as well as targeted therapies for patients with a BRAF or MEK gene mutation, but there are no effective treatments approved for patients with metastatic (spreading) or nonresectable (cannot be removed by surgery) melanoma whose disease progressed (got worse) after using an immune checkpoint inhibitor, or a BRAF or MEK inhibitor for those with gene mutations.
Keytruda New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma
Lymphoma
Treatment with the PD-1 inhibitor Keytruda (permbrolizumab) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with Adcetris (brentuximab vedotin), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
Page 1 of 4
Results 1 - 10 of 34

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest